AgingResearch.NewsJoin free

Osalmid + navitoclax

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 2 more
  • Animals1

Outcomes

1

Clear cell renal cell carcinoma

downin humans1

1 study

  1. Osalmid + navitoclax protects against clear cell renal cell carcinoma in humans.

    “the combination of the choleretic drug osalmid targeting RRM2 and the senolytic compound navitoclax targeting BCL-XL represents a novel therapeutic approach for ccRCC”

    Animalsin ccRCC cells and preclinical models

    Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway

    Cancer letters31 Jan 2025

More on Clear cell renal cell carcinoma

Latest

Related